LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial
Erik N. Mayer(Dana-Farber Cancer Institute), Sara M. Tolaney(Dana-Farber Cancer Institute), M.V. Martín(Hospital General Universitario Gregorio Marañón), Gregory A. Vidal(West Cancer Center), Luca Moscetti(Azienda Ospedaliero-Universitaria di Modena), K. Jhaveri(Memorial Sloan Kettering Cancer Center), Adam Brufsky(UPMC Hillman Cancer Center), William J. Gradishar(Northwestern University), Andreas Schneeweiß(German Cancer Research Center), Naoki Niikura(Tokai University), AM Favret(Virginia Cancer Specialists), Marcos E. Alfie(Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno), Kwang Suk Lee(National Cancer Center), Sobia Khan(University of Nottingham), M Feldman(Kaiser Permanente South San Francisco Medical Center), Bann-mo Day(Kaiser Permanente South San Francisco Medical Center), Linda Lam(Atotech (United States)), W. Darbonne(Kaiser Permanente South San Francisco Medical Center), P.D. Perez Moreno(Atotech (United States)), Hope Rugo(City of Hope)
Cited by 9
Abstract
Related Papers
No related papers found
Powered by citation graph analysis